A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL
- Status
- COMPLETED
- Phase
- PHASE3
Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT
- Status
- TERMINATED
- Phase
- N/A
A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.
- Status
- TERMINATED
- Phase
- PHASE2
Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab (Protocol R-GVHD)
- Status
- COMPLETED
- Phase
- PHASE2
CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
- Status
- COMPLETED
- Phase
- PHASE2
SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy
- Status
- COMPLETED
- Phase
- PHASE3
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL
- Status
- COMPLETED
- Phase
- PHASE2
Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy of Rituximab in Acute Cellular Rejection in Renal Transplant Patients
- Status
- TERMINATED
- Phase
- PHASE3
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
- Status
- TERMINATED
- Phase
- PHASE2
Rituximab Maintenance After Autologous Transplantation
- Status
- TERMINATED
- Phase
- PHASE3
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
- Status
- COMPLETED
- Phase
- PHASE2
Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
RituxiMab INDuction in Renal Transplantation
- Status
- UNKNOWN
- Phase
- PHASE4
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1